DGAP-News: B.R.A.I.N. Biotechnology Research And Information Network AG: Internationalization of Business Activities - BRAIN AG establishes US subsidiary to strengthen business development in North America

DGAP-News: B.R.A.I.N. Biotechnology Research And Information Network AG / Key word(s): Strategic Company Decision B.R.A.I.N. Biotechnology Research And Information Network AG: Internationalization of Business Activities - BRAIN AG establishes US subsidiary to strengthen business development in North America 06.03.2018 / 09:00 The issuer is solely responsible for the content of this announcement. --------------------------------------------------------------------------- Internationalization of Business Activities BRAIN AG establishes US subsidiary to strengthen business development in North America * More effective addressing of attractive target markets and improved customer relationships * Synergies with US presence of subsidiary AnalytiCon Discovery LLC Zwingenberg March 6, 2018 In order to address the North American markets of importance for the BRAIN Group more effectively, the German bio-economy pioneer BRAIN AG, headquartered in Zwingenberg, has founded the US subsidiary B.R.A.I.N. Biotechnology Research and Information Network US LLC (short: BRAIN LLC). This strategic step is intended to accelerate the internationalization of BRAIN's business operations, improve customer relations and intensify the Group's business development with a US presence. In addition, the company plans to expand its links with international research co-operations, in which BRAIN is already involved to some extent successfully. The newly founded BRAIN LLC is based in Rockville, Maryland, near Washington DC. After the company was founded and recorded in the previous month it now starts operations. BRAIN AG holds 100% of the shares in BRAIN LLC. Nearby BRAIN LLC is the US representative office of the BRAIN subsidiary Analyticon Discovery GmbH, Potsdam. BRAIN Group expects synergies and faster market access for its own product and process developments through the co-operation of the two US branches. BRAIN AG has taken a series of strategic measures since the beginning of the financial year 2017/18 with the aim of expanding business development and market access for BRAIN innovations. Dr. Jürgen Eck, CEO of BRAIN AG, commented: "The establishment of BRAIN LLC in the US state of Maryland is aimed at driving forward the internationalization of our business development. In order to be able to market our product and process innovations in the important future market of bio-economics more effectively internationally in the future, direct market access is of great importance. Our M&A strategy and the preparation of product-specific spin-offs to strengthen our product-driven business segment BioIndustrial also contribute to this." BRAIN AG and Analyticon Discovery GmbH are already partners in important product developments of BRAIN Group such as the DOLCE program for the development of biological sugar substitutes and sweetener enhancers. Several US companies have already been acquired as development partners in this program. BRAIN and Analyticon Discovery also work closely together in other development programs based on naturally derived active ingredients for different target industries. In addition to the targeted reduction of sugar in the food industry, this also applies to the reduction of salt and fat in foods and beverages as well as natural substances that prevent harmful germs and spoilage of food products. This includes, for example, the PerillicActive development program for natural active ingredients based on fermented orange oil. About BRAIN B.R.A.I.N. Biotechnology Research and Information Network AG (BRAIN AG; ISIN DE0005203947 / WKN 520394) is one of Europe's leading technology companies in the field of industrial biotechnology, the core discipline of Bioeconomy. As such, BRAIN identifies previously untapped, efficient enzymes, microbial producer organisms or natural substances from complex biological systems that can be put to industrial use. The innovative solutions and products developed by help of this "Toolbox of Nature" are successfully applied in the chemistry, the cosmetics and the food industries. BRAIN's business model is based on two pillars - BioScience and BioIndustrial. The BioScience comprises its frequently exclusive collaboration business with industrial partners. BioIndustrial comprises the development and commercialization of BRAIN's own products and active product components. Further information is available at www.brain-biotech.de/en. BžRžAžIžN Biotechnology Research And Information Network AG Darmstädter Str. 34-36 64673 Zwingenberg Germany www.brain-biotech.de Contact Media Thomas Deichmann Head of Public Relations Tel.: +49-(0)-6251-9331-72 Fax: +49-(0)-6251-9331-11 E-Mail: [email protected] Contact Investor Relations Dr. Martin Langer Executive Vice President Corporate Development Tel.: +49-(0)-6251-9331-16 Fax: +49-(0)-6251-9331-11 E-Mail: [email protected] Follow us on Twitter https://twitter.com/BRAINbiotech Disclaimer This press release contains forward-looking statements. These statements reflect the current views, expectations, and assumptions of the management of BRAIN AG and are based on information currently available to the management. Forward-looking statements are not guarantees of future performance and involve known and unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. There are numerous factors which could influence the future performance by and future developments at BRAIN AG and the BRAIN group of companies. Such factors include, but are not limited to, changes in the general economic and competitive environment, risks associated with capital markets, currency exchange rate fluctuations, changes in international and national laws and regulations, in particular with respect to tax laws and regulations, and other factors. BRAIN AG does not undertake any obligation to update or revise any forward-looking statements. --------------------------------------------------------------------------- 06.03.2018 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.de --------------------------------------------------------------------------- Language: English Company: B.R.A.I.N. Biotechnology Research And Information Network AG Darmstädter Straße 34-36 64673 Zwingenberg Germany Phone: +49 (0) 62 51 / 9331-0 Fax: +49 (0) 62 51 / 9331-11 E-mail: [email protected] Internet: www.brain-biotech.de ISIN: DE0005203947 WKN: 520394 Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange End of News DGAP News Service --------------------------------------------------------------------------- 660439 06.03.2018

Die wichtigsten Finanzdaten auf einen Blick
  2015 2016 2017 2018 2019 2020 2021e
Umsatzerlöse1 21,13 22,79 24,11 27,05 38,56 38,23 0,00
EBITDA1,2 -3,10 -12,36 -7,70 -6,55 -2,50 -3,88 0,00
EBITDA-Marge3 -14,67 -54,23 -31,94 -24,21 -6,48 -10,15 0,00
EBIT1,4 -4,57 -13,81 -9,37 -9,57 -7,20 -8,23 0,00
EBIT-Marge5 -21,63 -60,60 -38,86 -35,38 -18,67 -21,53 0,00
Jahresüberschuss1 -5,47 -14,43 -9,40 -8,37 -11,12 -9,02 0,00
Netto-Marge6 -25,89 -63,32 -38,99 -30,94 -28,84 -23,59 0,00
Cashflow1,7 -4,11 -8,68 -5,80 -5,42 -3,38 -4,77 0,00
Ergebnis je Aktie8 -0,36 -0,97 -0,58 -0,45 -0,61 -0,52 -0,18
Dividende8 0,00 0,00 0,00 0,00 0,00 0,00 0,00
Quelle: boersengefluester.de und Firmenangaben

  Geschäftsbericht 2020 - Kostenfrei herunterladen.  
1 in Mio. Euro; 2 EBITDA = Ergebnis vor Zinsen, Steuern und Abschreibungen; 3 EBITDA in Relation zum Umsatz; 4 EBIT = Ergebnis vor Zinsen und Steuern; 5 EBIT in Relation zum Umsatz; 6 Jahresüberschuss (-fehlbetrag) in Relation zum Umsatz; 7 Cashflow aus der gewöhnlichen Geschäftstätigkeit; 8 in Euro; Quelle: boersengefluester.de

Wirtschaftsprüfer: Ernst & Young

BRAIN Biotech
WKN Kurs in € Einschätzung Börsenwert in Mio. €
520394 10,050 199,61
KGV 2022e KGV 10Y-Ø BGFL-Ratio Shiller-KGV
0,00 18,27 0,00 -21,11
11,25 - 5,22 -55,14
Dividende '19 in € Dividende '20e in € Div.-Rendite '20e
in %
0,00 0,00 0,00 10.03.2021
Q1-Zahlen Q2-Zahlen Q3-Zahlen Bilanz-PK
26.02.2021 28.05.2021 30.08.2021 14.01.2021
Abstand 60Tage-Linie Abstand 200Tage-Linie Performance YtD Performance 52 Wochen
7,05% 16,10% 11,17% 16,86%
Weitere Ad-hoc und Unternehmensrelevante Mitteilungen zu B.R.A.I.N. Biotechnology Research And Information Network AG  ISIN: DE0005203947 können Sie bei DGAP abrufen

Biotechnologie , 520394 , BNN , XETR:BNN